Lifecore Biomedical (LFCR) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Lifecore Biomedical (LFCR) over the past year, gaining 53.0% versus a loss of 6.4%. Over five years, LFCR leads with a -34.5% price change compared with -96.6% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $244.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFCR | ZNTL |
|---|---|---|
| Share price | $6.45 | $2.64 |
| Market cap | $244.49M | $259.04M |
| 1-day change | +0.31% | +5.18% |
| YTD return | -21.39% | +85.93% |
| 1-year return | -6.40% | +53.05% |
| 5-year return | -34.45% | -96.65% |
| EPS (TTM) | $-1.27 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.98 | $6.95 |
| 52-week low | $3.63 | $1.21 |
| Distance from 52-week high | -28.17% | -62.01% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -2.64% | +177.65% |
| Average volume | 294.61K | 1.21M |
| Shares outstanding | 37.91M | 98.12M |
| Employees | 382 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed LFCR by 59.5 percentage points over the past year.
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
LFCR vs ZNTL FAQ
Which is bigger, Lifecore Biomedical or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $244.49M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, LFCR or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with -6.40% for LFCR (price return, excluding dividends). Past performance does not predict future results.
Are Lifecore Biomedical and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.